• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of pharmaceutical sciences >The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations
【24h】

The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations

机译：新型抗糖尿病黄嘌呤衍生物及其基于壳聚糖制剂的安全性曲线

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The safety profile of new antidiabetic xanthine derivatives with thiazolidine-4-one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7), administrated to diabetic rats, have been evaluated in terms of biochemical markers of liver and kidney function as well as of hematological markers. The effect on lipid profile and clinic parameters (body weight, food and water intake) has been also evaluated. The treatment of diabetic rats with xanthine derivatives (6, 7) and chitosan based formulations (CS-6, CS-7) was associated with lower liver enzymes (AST, ALT, LDH) and bilirubin (direct, total) values compared to the non-treated diabetic rats, that means the tested derivatives/formulations have improved the liver function injured in diabetes mellitus conditions. Also the kidney biochemical markers (creatinine, uric acid, urea) were significantly decreased in diabetic rats treated with 6, 7 and chitosan microparticles (CS-6, CS-7). The values of biochemical markers of liver and kidney functions were even better than the values recorded for pioglitazone, used as standard antidiabetic drug. The improving effect on kidney function was proved by the histopathological study. Moreover, the xanthine derivatives and their chitosan based formulation were associated with improved hematological markers compared to the non-treated diabetic rats which mean the improving of the hemorheological state. These results support the safety profile of new xanthine derivatives with thiazolidine-4-one scaffold (6, 7) and their new chitosan based formulations (CS-6, CS-7) and their potential applications for the treatment of diabetes mellitus syndrome.
机译：新的抗糖苷酮衍生物与噻唑烷-4-一个支架（6,7）及其新的壳聚糖基配方（CS-6，CS-7）的安全性突发，并在生物化学标记方面进行了评估肝脏和肾功能以及血液学标记。还评估了对脂质谱和临床参数（体重，食物和水摄入）的影响。与黄嘌呤衍生物（6,7）和壳聚糖基配制剂（CS-6，CS-7）的治疗与下肝酶（AST，ALT，LDH）和胆红素（直接，总）值相关的糖尿病大鼠非处理过的糖尿病大鼠，这意味着测试的衍生物/配方在糖尿病病症中改善了肝功能。在用6,7和壳聚糖微粒（CS-6，CS-7）处理的糖尿病大鼠中，肾脏生化标记物（肌酐，尿酸，尿素）显着降低（CS-6，CS-7）。肝脏和肾功能的生化标志物的值甚至比为吡格列酮记录的值更好，用作标准抗糖尿病药物。通过组织病理学研究证明了对肾功能的改善作用。此外，与未治疗的糖尿病大鼠相比，黄原衍生物及其壳聚糖基制剂与改善的血液学标志物相关，这意味着改善血液流变态。这些结果支持新的黄嘌呤衍生物与噻唑烷-4-一个支架（6,7）及其新的壳聚糖基配方（CS-6，CS-7）及其潜在应用，以及治疗糖尿病综合征的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号